Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers - PubMed (original) (raw)
. 2004 Jan 1;64(1):64-71.
doi: 10.1158/0008-5472.can-03-2570.
Ming Lin, Lee-Jen Wei, Cheng Li, Alexander Miron, Gabriella Lodeiro, Lyndsay Harris, Sridhar Ramaswamy, David M Tanenbaum, Matthew Meyerson, James D Iglehart, Andrea Richardson
Affiliations
- PMID: 14729609
- DOI: 10.1158/0008-5472.can-03-2570
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers
Zhigang C Wang et al. Cancer Res. 2004.
Abstract
Gene expression array profiles identify subclasses of breast cancers with different clinical outcomes and different molecular features. The present study attempted to correlate genomic alterations (loss of heterozygosity; LOH) with subclasses of breast cancers having distinct gene expression signatures. Hierarchical clustering of expression array data from 89 invasive breast cancers identified four major expression subclasses. Thirty-four of these cases representative of the four subclasses were microdissected and allelotyped using genome-wide single nucleotide polymorphism detection arrays (Affymetrix, Inc.). LOH was determined by comparing tumor and normal single nucleotide polymorphism allelotypes. A newly developed statistical tool was used to determine the chromosomal regions of frequent LOH. We found that breast cancers were highly heterogeneous, with the proportion of LOH ranging widely from 0.3% to >60% of heterozygous markers. The most common sites of LOH were on 17p, 17q, 16q, 11q, and 14q, sites reported in previous LOH studies. Signature LOH events were discovered in certain expression subclasses. Unique regions of LOH on 5q and 4p marked a subclass of breast cancers with "basal-like" expression profiles, distinct from other subclasses. LOH on 1p and 16q occurred preferentially in a subclass of estrogen receptor-positive breast cancers. Finding unique LOH patterns in different groups of breast cancer, in part defined by expression signatures, adds confidence to newer schemes of molecular classification. Furthermore, exclusive association between biological subclasses and restricted LOH events provides rationale to search for targeted genes.
Similar articles
- Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer.
Loo LW, Ton C, Wang YW, Grove DI, Bouzek H, Vartanian N, Lin MG, Yuan X, Lawton TL, Daling JR, Malone KE, Li CI, Hsu L, Porter PL. Loo LW, et al. Genes Chromosomes Cancer. 2008 Dec;47(12):1049-66. doi: 10.1002/gcc.20610. Genes Chromosomes Cancer. 2008. PMID: 18720524 Free PMC article. - Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays.
Argos M, Kibriya MG, Jasmine F, Olopade OI, Su T, Hibshoosh H, Ahsan H. Argos M, et al. Cancer Genet Cytogenet. 2008 Apr 15;182(2):69-74. doi: 10.1016/j.cancergencyto.2008.01.001. Cancer Genet Cytogenet. 2008. PMID: 18406867 Free PMC article. - ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism.
Cleton-Jansen AM, van Eijk R, Lombaerts M, Schmidt MK, Van't Veer LJ, Philippo K, Zimmerman RM, Peterse JL, Smit VT, van Wezel T, Cornelisse CJ. Cleton-Jansen AM, et al. BMC Cancer. 2008 Apr 16;8:105. doi: 10.1186/1471-2407-8-105. BMC Cancer. 2008. PMID: 18416817 Free PMC article. - Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X, Porter AT, Honn KV. Gao X, et al. Adv Exp Med Biol. 1997;407:41-53. doi: 10.1007/978-1-4899-1813-0_7. Adv Exp Med Biol. 1997. PMID: 9321930 Review. - [Molecular genetic progression on nasopharyngeal carcinoma].
Shao JY, Zeng WF, Zeng YX. Shao JY, et al. Ai Zheng. 2002 Jan;21(1):1-10. Ai Zheng. 2002. PMID: 12500388 Review. Chinese.
Cited by
- The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
Ng CW, Tsang YTM, Gershenson DM, Wong KK. Ng CW, et al. Br J Cancer. 2024 May;130(11):1875-1884. doi: 10.1038/s41416-024-02668-w. Epub 2024 Apr 6. Br J Cancer. 2024. PMID: 38582811 Free PMC article. - Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer.
Khella CA, Mehta GA, Mehta RN, Gatza ML. Khella CA, et al. J Pers Med. 2021 Feb 19;11(2):149. doi: 10.3390/jpm11020149. J Pers Med. 2021. PMID: 33669749 Free PMC article. Review. - Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Nicolas E, et al. Cancers (Basel). 2018 Dec 11;10(12):506. doi: 10.3390/cancers10120506. Cancers (Basel). 2018. PMID: 30544963 Free PMC article. Review. - Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M, Mott KR, Hollern DP, Fan C, Darr DB, Perou CM. Tanioka M, et al. Genome Med. 2018 Nov 30;10(1):86. doi: 10.1186/s13073-018-0597-3. Genome Med. 2018. PMID: 30497520 Free PMC article. - Apigenin, a dietary flavonoid, induces apoptosis, DNA damage, and oxidative stress in human breast cancer MCF-7 and MDA MB-231 cells.
Vrhovac Madunić I, Madunić J, Antunović M, Paradžik M, Garaj-Vrhovac V, Breljak D, Marijanović I, Gajski G. Vrhovac Madunić I, et al. Naunyn Schmiedebergs Arch Pharmacol. 2018 May;391(5):537-550. doi: 10.1007/s00210-018-1486-4. Epub 2018 Mar 14. Naunyn Schmiedebergs Arch Pharmacol. 2018. PMID: 29541820
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical